1.94
0.09 (4.86%)
| Previous Close | 1.85 |
| Open | 1.89 |
| Volume | 2,503 |
| Avg. Volume (3M) | 9,795 |
| Market Cap | 70,195,216 |
| Price / Book | 4.06 |
| 52 Weeks Range | |
| Earnings Date | 19 Mar 2025 - 24 Mar 2025 |
| Operating Margin (TTM) | -1,130.87% |
| Diluted EPS (TTM) | -1.15 |
| Quarterly Revenue Growth (YOY) | 21.40% |
| Current Ratio (MRQ) | 0.250 |
| Operating Cash Flow (TTM) | -38.55 M |
| Levered Free Cash Flow (TTM) | -31.06 M |
| Return on Assets (TTM) | -25.09% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Armata Pharmaceuticals, Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.5 |
| Average | -1.13 |
|
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 70.25% |
| % Held by Institutions | 3.82% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Edgewood Management Llc | 30 Sep 2024 | 100,000 |
| Seacrest Wealth Management, Llc | 30 Sep 2024 | 34,954 |
| Captrust Financial Advisors | 30 Sep 2024 | 13,140 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |